SYRS — Syros Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.07m
- -$16.12m
- $9.94m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -197.27% | ||
| Return on Equity | -776.96% | ||
| Operating Margin | -28927.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.98 | 15.09 | 23.49 | 14.88 | 9.94 | n/a | n/a | 37.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Directors
- Peter Wirth NEC (70)
- Nancy Simonian PRE (60)
- Jason Haas CFO (54)
- Eric Olson CSO (63)
- Gerald Quirk OTH (53)
- David Roth OTH (58)
- Deborah Dunsire DRC (59)
- Richard Young DRC (67)
- Srinivas Akkaraju IND (53)
- Mark Alles IND (61)
- S. Gail Eckhardt IND (63)
- Marsha Fanucci IND (67)
- Amir Nashat IND (47)
- Phillip Sharp IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- November 9th, 2011
- Public Since
- June 30th, 2016
- No. of Shareholders
- 73
- No. of Employees
- 68
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 26,832,457
- Address
- 35 Cambridge Park Drive, CAMBRIDGE, 02140
- Web
- https://syros.com/
- Phone
- +1 6177441340
- Contact
- Hannah Deresiewicz
- Auditors
- Ernst & Young LLP
Upcoming Events for SYRS
Syros Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Syros Pharmaceuticals Inc Earnings Release
Q3 2025 Syros Pharmaceuticals Inc Earnings Release
Similar to SYRS
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Syros Pharmaceuticals share price?
As of Today at 23:33 UTC, shares in Syros Pharmaceuticals are trading at $0.04. This share price information is delayed by 15 minutes.
How has the Syros Pharmaceuticals share price performed this year?
Shares in Syros Pharmaceuticals last closed at $0.04 and the price had moved by -99.23% over the past 365 days. In terms of relative price strength the Syros Pharmaceuticals share price has underperformed the S&P500 Index by -99.29% over the past year.
What are the analyst and broker recommendations for Syros Pharmaceuticals?
The overall consensus recommendation for Syros Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Syros Pharmaceuticals dividend yield?
Syros Pharmaceuticals does not currently pay a dividend.
Does Syros Pharmaceuticals pay a dividend?
Syros Pharmaceuticals does not currently pay a dividend.
When does Syros Pharmaceuticals next pay dividends?
Syros Pharmaceuticals does not currently pay a dividend.
How do I buy Syros Pharmaceuticals shares?
To buy shares in Syros Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Syros Pharmaceuticals?
As of the previous close price of $0.04, shares in Syros Pharmaceuticals had a market capitalisation of $1.07m.
Where are Syros Pharmaceuticals shares listed?
Here are the trading details for Syros Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SYRS
What kind of share is Syros Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Syros Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Syros Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Syros Pharmaceuticals is $20.00. That is 49900% above the last closing price of $0.04.
Analysts covering Syros Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
Find out moreWhat is the trend in the Syros Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Syros Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -98.23%.
As of the last closing price of $0.04, shares in Syros Pharmaceuticals were trading -96.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Syros Pharmaceuticals PE Ratio?
The Syros Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Syros Pharmaceuticals?
Syros Pharmaceuticals' management team is headed by:
- Peter Wirth - NEC
- Nancy Simonian - PRE
- Jason Haas - CFO
- Eric Olson - CSO
- Gerald Quirk - OTH
- David Roth - OTH
- Deborah Dunsire - DRC
- Richard Young - DRC
- Srinivas Akkaraju - IND
- Mark Alles - IND
- S. Gail Eckhardt - IND
- Marsha Fanucci - IND
- Amir Nashat - IND
- Phillip Sharp - IND